English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  To evaluate the use of recombinant human fibroblast growth factor (rh FGF )‐2 in combination with deproteinized bovine bone mineral ( DBBM ) compared with rh FGF ‐2 alone, in the treatment of intrabony periodontal defects.    Materials and Methods  Patients with periodontitis who had received initial periodontal therapy and had intrabony defects of ≥ 3 mm in depth were enrolled. Sites were randomly assigned to receive a commercial formulation of 0.3% rh FGF ‐2 +  DBBM  (test) or rh FGF ‐2 alone (control). Clinical parameters and a patient‐reported outcome measure ( PROM ) were evaluated at baseline and at 3 and 6 months postoperatively.    Results  Twenty‐two sites in each group were evaluated. A significant improvement in clinical attachment level ( CAL ) from baseline was observed in both groups at 6 months postoperatively.  CAL  gain was 3.16 ± 1.45 mm in the test group and 2.77 ± 1.15 mm in the control group, showing no significant difference between groups. Radiographic bone fill was significantly greater in the test group (47.2%) than in the control group (29.3%). No significant difference in  PROM  between groups was observed.    Conclusions  At 6 months, no significant difference in  CAL  gain or  PROM  between the two treatments was observed, although combination therapy yielded an enhanced radiographic outcome.

journal of clinical periodontology

Treatment of intrabony periodontal defects using rh FGF ‐2 in combination with deproteinized bovine bone mineral or rh FGF ‐2 alone: A 6‐month randomized controlled trial